AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of AZD2171 in treating young
patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking
blood flow to the tumor.